Patent · US Active

Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases

US11053235B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

Janssen Sciences Ireland Unlimited Company · IE

Inventors

Gang Deng · Benicia, US
Yimin Jiang · Londonderry, US
Qian Liu · Suzhou, CN
Chao Liang · Beijing, CN
Zhao-Kui Wan · Lexington, US
Wing S. Cheung · Plainsboro, US
Zhanling Cheng · Shanghai, CN
Yanping Xu · Noblesville, US

Key dates

Filing date	Aug 9, 2019
Grant date	Jul 6, 2021
Priority date	—
Expiry date	Aug 9, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10111
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.